Across two pivotal trials in patients with uncontrolled hypertension,

BAXFENDY was well tolerated

EXPLORE BAXFENDY / SAFETY

Adverse reactions reported in ≥2% of patients treated with BAXFENDY and greater (≥1%) than placebo during the 12-week period in pooled, placebo-controlled hypertension trials.[1a]

Event BAXFENDY 2 mg[*]
(n=441)
%		 BAXFENDY 1 mg[†]
(n=333)
%		 Placebo[‡]
(n=442)
%
Hyperkalemia 10.2 6.6 2.5
Hypotension 3.6 2.1 0.5
Hyponatremia 3.2 2.1 0.9
Dizziness 2.9 3.0 0.9
Muscle spasms 2.9 1.8 0.7

*Frequencies derived from the pool of three hypertension studies (BaxHTN, BrigHTN, Bax24) with BAXFENDY 2 mg as add-on treatment.[1b]

†Frequencies derived from the pool of two hypertension studies (BaxHTN, BrigHTN) with BAXFENDY 1 mg as add-on treatment.[1c]

‡Frequencies derived from the pool of three hypertension studies (BaxHTN, BrigHTN, Bax24) with BAXFENDY 1 mg and/or 2 mg as add-on treatment.[1d]

Warnings and Precautions[1e]

BAXFENDY can cause hyperkalemia and hyponatremia. Assess serum potassium and sodium levels before initiating therapy and correct if needed, monitor periodically during treatment.

Low rates of discontinuation due to hyperkalemia[1f]

  • BAXFENDY 2 mg[*] (n=441): 1.8%
  • BAXFENDY 1 mg[†] (n=333): 0.6%
  • Placebo[‡] (n=442): 0%


 

Discontinuation rates due to any AEs[§]

BaxHTN[2a]:
  • BAXFENDY 2 mg (n=266) = 4.5%
  • BAXFENDY 1 mg (n=264) = 2.7%
  • Placebo (n=264) = 1.9%
Bax24[3a]:
  • BAXFENDY 2 mg (n=108) = 5.0%
  • Placebo (n=109) = 0%

§Reasons for discontinuation in patients who received BAXFENDY: hyperkalemia, hyponatremia, arthralgia, lower respiratory tract infection, hypertension, hypotension, hepatobiliary disorders, and increased serum potassium.[4]


 

In BaxHTN and Bax24, with BAXFENDY[2b],[3b],[5]:

  • NO REPORTS of adrenal insufficiency
  • NO REPORTS of gynecomastia

CHANGES IN SERUM POTASSIUM WITH BAXFENDY OCCURRED PREDOMINANTLY IN THE FIRST TWO WEEKS AND THEN STABILIZED

BaxHTN: Mean Change in Serum Potassium From Baseline to Week 12[2c]

Serum Potassium with BAXFENDY Study GraphSerum Potassium with BAXFENDY Study Graph

Serum potassium increased by an average of 0.4 mmol/L in the first two weeks[||] of therapy with BAXFENDY 2 mg[6]

||^ Mean baseline serum potassium was 4.2 mmol/L.

Assess serum potassium levels before initiating treatment and monitor periodically thereafter, particularly in patients with increased risk of developing hyperkalemia[1g]

With BAXFENDY By Your Side, prescribe with confidence

FIND SUPPORT RESOURCES

Abbreviation: AE=adverse event.

References:

  1. 1a 1b 1c 1d 1e 1f 1g BAXFENDY® (baxdrostat) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
  2. 2a 2b 2c Flack JM, Azizi M, Brown JM, et al; BaxHTN Investigators. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension [including online supplement].
N Engl J Med. 2025;393(14):1363-1374.
  3. 3a 3b Azizi M, Brown JM, Dwyer JP, et al; Bax24 investigators. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial [including online supplement]. Lancet. 2026;407(10532):988-999.
  4. ^ Data on File, REF-331193. AZPLP.
  5. ^ Data on File, REF-331530. AZPLP.
  6. ^ Data on File, REF-331723. AZPLP.